We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.12 | 6.77966101695 | 1.77 | 1.9735 | 1.74 | 467747 | 1.86655316 | CS |
4 | -0.22 | -10.4265402844 | 2.11 | 2.44 | 1.74 | 716186 | 2.07394178 | CS |
12 | 0.19 | 11.1764705882 | 1.7 | 2.655 | 1.64 | 809251 | 2.14464719 | CS |
26 | -0.33 | -14.8648648649 | 2.22 | 2.655 | 1.51 | 960712 | 2.00288606 | CS |
52 | -0.69 | -26.7441860465 | 2.58 | 3.375 | 1.51 | 798223 | 2.24663267 | CS |
156 | -14.01 | -88.1132075472 | 15.9 | 24.47 | 1.51 | 723803 | 6.02481298 | CS |
260 | -14.01 | -88.1132075472 | 15.9 | 24.47 | 1.51 | 723803 | 6.02481298 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions